Thanos Panayotis K, Michaelides Michael, Benveniste Helene, Wang Gene Jack, Volkow Nora D
Behavioral Neuropharmacology and NeuroImaging Lab, Medical Department, Building 490, Brookhaven National Laboratory, Upton, NY 11973-5000, United States.
Pharmacol Biochem Behav. 2007 Oct;87(4):426-33. doi: 10.1016/j.pbb.2007.05.020. Epub 2007 Jun 5.
Methylphenidate (MP) and amphetamine, which are the mainstay for the treatment of ADHD, have raised concerns because of their reinforcing effects and the fear that their chronic use during childhood or adolescence could induce changes in the brain that could facilitate drug abuse in adulthood.
Here we measured the effects of chronic treatment (8 months) with oral MP (1 or 2 mg/kg), which was initiated in periadolescent rats (postnatal day 30). Following this treatment, rats were tested on cocaine self-administration. In addition at 2 and 8 months of treatment we measured dopamine D2 receptor (D2R) availability in the striatum using [(11)C]raclopride microPET (microPET) imaging.
Animals treated for 8 months with 2 mg/kg of MP showed significantly reduced rates of cocaine self-administration at adulthood than vehicle treated rats. D2R availability in the striatum was significantly lower in rats after 2 months of treatment with MP (1 and 2 mg/kg) but significantly higher after 8 months of MP treatment than in the vehicle treated rats. In vehicle treated rats D2R availability decreased with age whereas it increased in rats treated with MP. Because low D2R levels in the striatum are associated with a propensity for self-administration of drugs both in laboratory animals and in humans, this effect could underlie the lower rates of cocaine self-administration observed in the rats given 8 months of treatment with MP.
Eight month treatment with oral MP beginning in adolescence decreased cocaine-self administration (1 mg/kg) during adulthood which could reflect the increases in D2R availability observed at this life stage since D2R increases are associated with reduced propensity for cocaine self administration. In contrast, two month treatment with MP started also at adolescence decreased D2R availability, which could raise concern that at this life stage short treatments could possibly increase vulnerability to drug abuse during adulthood. These findings indicate that MP effects on D2R expression in the striatum are sensitive not only to length of treatment but also to the developmental stage at which treatment is given. Future studies evaluating the effects of different lengths of treatment on drug self-administration are required to assess optimal duration of treatment regimes to minimize adverse effects on the propensity for drug self administration.
哌甲酯(MP)和苯丙胺是治疗注意力缺陷多动障碍(ADHD)的主要药物,但因其强化作用以及担心在儿童期或青少年期长期使用可能会引起大脑变化,进而在成年期易引发药物滥用,引发了人们的关注。
在此,我们测量了围青春期大鼠(出生后第30天)口服MP(1或2毫克/千克)进行慢性治疗(8个月)的效果。治疗后,对大鼠进行可卡因自我给药测试。此外,在治疗的第2个月和第8个月,我们使用[(11)C]雷氯必利微型正电子发射断层扫描(微型PET)成像测量纹状体中多巴胺D2受体(D2R)的可用性。
用2毫克/千克MP治疗8个月的动物在成年期可卡因自我给药率显著低于用赋形剂处理的大鼠。用MP(1和2毫克/千克)治疗2个月后,大鼠纹状体中D2R的可用性显著降低,但MP治疗8个月后比用赋形剂处理的大鼠显著升高。在赋形剂处理的大鼠中,D2R可用性随年龄降低,而在用MP处理的大鼠中则升高。由于纹状体中低水平的D2R与实验动物和人类的药物自我给药倾向有关,这种效应可能是在用MP治疗8个月的大鼠中观察到可卡因自我给药率较低的原因。
青春期开始口服MP进行8个月治疗可降低成年期可卡因自我给药(1毫克/千克),这可能反映了在这个生命阶段观察到的D2R可用性增加,因为D2R增加与可卡因自我给药倾向降低有关。相比之下,同样在青春期开始用MP进行2个月治疗会降低D2R可用性,这可能引发人们担心在这个生命阶段短期治疗可能会增加成年期药物滥用的易感性。这些发现表明,MP对纹状体中D2R表达的影响不仅对治疗时长敏感,而且对给药时的发育阶段敏感。需要进一步研究评估不同治疗时长对药物自我给药的影响,以确定最佳治疗疗程,尽量减少对药物自我给药倾向的不利影响。